Previous 10 | Next 10 |
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that the company will participate in the Cowen 40 th Annual Healthcare Conference in Boston. Chief Executive Officer Robert G. Finizio will provide an overview of the company at the conferen...
TherapeuticsMD ( TXMD ) recently reported their Q4/2019 earnings that revealed that their 2019 efforts have set up 2020 to be a year of substantial revenue growth. The company was dedicated to launching their product portfolio, confirming payer wins, and transforming TXMD's overall focus fro...
Image source: The Motley Fool. TherapeuticsMD Inc (NASDAQ: TXMD) Q4 2019 Earnings Call Feb 20, 2020 , 8:30 a.m. ET Operator Continue reading
TherapeuticsMD, Inc. (TXMD) Q4 2019 Earnings Conference Call February 20, 2020 08:30 ET Company Participants Nichol Ochsner - VP, IR Robert Finizio - CEO Dawn Halkuff - Chief Commercial Officer Dan Cartwright - CFO Conference Call Participants Louise Chen - Cantor Fitzger...
Gainers: Brickell Biotech (NASDAQ: BBI ) +80% . More news on: Brickell Biotech, Inc., Stamps.com Inc., Adesto Technologies Corporation, Stocks on the move, , Read more ...
The following slide deck was published by TherapeuticsMD, Inc. in conjunction with their 2019 Q4 earnings Read more ...
Are These The Best Penny Stocks To Buy For Under $3 Right Now? Penny stocks are highly speculative and highly volatile. But the one thing all of these cheap stocks have in common is the price. According to the Securities and Exchange Commission’s definition of penny stocks , these ar...
Therapeutics MD ( TXMD ) Q4 results : More news on: TherapeuticsMD, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more ...
Therapeutics MD (NASDAQ: TXMD ): Q4 GAAP EPS of -$0.19 in-line. More news on: TherapeuticsMD, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
- 4Q19 Total Net Product Revenue of $15.9 Million Exceeded the Company’s Financial Guidance - - Full-Year 2019 Total Net Product Revenue of $34.1 Million at the Top End of Financial Guidance - - Company Launched ANNOVERA, a Novel, Long-Lasting Contraceptive - - Company Expect...
News, Short Squeeze, Breakout and More Instantly...
TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Results Net Income (...
• Evaluation of strategic alternatives continues TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2023...